诚达药业
(301201)
| 流通市值：21.18亿 | | | 总市值：37.58亿 |
| 流通股本：8719.38万 | | | 总股本：1.55亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 479,133,966.54 | 942,397,244.75 | 1,202,901,471.61 | 1,363,938,914.78 |
| 应收票据及应收账款 | 73,246,021.66 | 104,410,746.63 | 109,063,174.94 | 124,872,079.24 |
| 其中：应收票据 | 1,688,200 | 3,782,995 | 411,200 | 250,000 |
| 应收账款 | 71,557,821.66 | 100,627,751.63 | 108,651,974.94 | 124,622,079.24 |
| 应收款项融资 | - | - | - | 1,808,850 |
| 预付款项 | 52,885,125.78 | 30,573,371.16 | 28,110,197.16 | 2,306,688.74 |
| 其他应收款合计 | 474,981.04 | 336,231 | 521,126.4 | 542,160.21 |
| 存货 | 128,366,651.49 | 117,462,582.36 | 115,584,134.66 | 130,470,314.55 |
| 其他流动资产 | 24,131,899.34 | 14,093,994.93 | 11,885,792.73 | 18,927,600.63 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,463,203,712.55 | 1,518,058,580.33 | 1,568,715,897.5 | 1,642,866,608.15 |
| 非流动资产: | | | | |
| 其他权益工具投资 | 30,000,000 | 30,000,000 | 30,000,000 | 30,000,000 |
| 投资性房地产 | 46,826,772.06 | 47,112,465.63 | 47,398,159.2 | 47,683,852.77 |
| 固定资产 | 453,728,377.98 | 458,343,638.86 | 468,031,521.59 | 467,039,987.02 |
| 在建工程 | 253,210,454.71 | 199,285,985 | 167,145,518.41 | 179,174,063.28 |
| 无形资产 | 33,035,642.97 | 33,306,858.36 | 33,578,073.75 | 33,849,289.14 |
| 长期待摊费用 | 35,751,760.2 | 37,928,924.64 | 40,527,906.42 | 43,503,289.37 |
| 递延所得税资产 | 3,876,534.02 | 3,745,883.55 | 4,211,431.2 | 4,294,194.6 |
| 其他非流动资产 | 75,755,317.59 | 79,066,690.9 | 44,140,746.42 | 6,913,733.82 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 932,184,859.53 | 888,790,446.94 | 835,033,356.99 | 812,458,410 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,395,388,572.08 | 2,406,849,027.27 | 2,403,749,254.49 | 2,455,325,018.15 |
| 流动负债: | | | | |
| 短期借款 | - | 600,000 | 2,670,000 | - |
| 应付票据及应付账款 | 146,386,538.8 | 133,953,086.86 | 129,731,884.15 | 139,885,259.26 |
| 其中：应付票据 | 22,925,615.7 | 19,041,318.8 | 15,255,860.88 | 31,786,955.46 |
| 应付账款 | 123,460,923.1 | 114,911,768.06 | 114,476,023.27 | 108,098,303.8 |
| 预收款项 | 101,570 | 103,064 | 44,303.41 | 283,183.41 |
| 合同负债 | 4,828,188.79 | 13,892,919.8 | 10,795,935.09 | 11,870,716.36 |
| 应付职工薪酬 | 1,133,000.58 | 2,541,711.54 | 2,452,878.65 | 5,122,293.91 |
| 应交税费 | 447,561.32 | -2,243,658.42 | 2,352,466.45 | 8,912,583.6 |
| 其他应付款合计 | 4,840,165.55 | 4,048,025.42 | 3,866,828.96 | 4,051,528.88 |
| 其他流动负债 | - | - | 1,407,045.47 | 1,407,045.47 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 157,737,025.04 | 152,895,149.2 | 153,321,342.18 | 171,532,610.89 |
| 非流动负债: | | | | |
| 递延收益 | 2,709,704.98 | 2,908,248.16 | 3,169,291.33 | 3,430,334.5 |
| 递延所得税负债 | 1,933,423.44 | 1,821,411.48 | 1,355,908.69 | 1,440,113.98 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 4,643,128.42 | 4,729,659.64 | 4,525,200.02 | 4,870,448.48 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 162,380,153.46 | 157,624,808.84 | 157,846,542.2 | 176,403,059.37 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 154,713,824 | 154,713,824 | 154,713,824 | 154,713,824 |
| 资本公积 | 1,693,874,093.68 | 1,693,687,823.68 | 1,693,501,553.68 | 1,693,315,283.68 |
| 减:库存股 | 57,073,347.67 | 55,278,100.14 | 51,931,802.68 | - |
| 盈余公积 | 55,907,973.27 | 55,907,973.27 | 55,907,973.27 | 55,907,973.27 |
| 未分配利润 | 383,264,221.12 | 398,361,493.36 | 391,831,207.29 | 373,186,701.29 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,230,686,764.4 | 2,247,393,014.17 | 2,244,022,755.56 | 2,277,123,782.24 |
| 少数股东权益 | 2,321,654.22 | 1,831,204.26 | 1,879,956.73 | 1,798,176.54 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,233,008,418.62 | 2,249,224,218.43 | 2,245,902,712.29 | 2,278,921,958.78 |
| 负债和股东权益合计 | 2,395,388,572.08 | 2,406,849,027.27 | 2,403,749,254.49 | 2,455,325,018.15 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-22 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |